Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative
Daewoong Pharmaceutical and HanAll Biopharma invest in the broad potential of Turn Biotechnologies Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea, April 11, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (KRX: 069620.KS) and HanAll Biopharma (KRX: 009420.KS) today announced expansion of their open collaboration strategy by...
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA antibody candidate at AACR (American Association for Cancer Research) 2022 Annual Meeting currently taking...
Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that it closed an oversubscribed fundraising round to support...
Frost & Sullivan Hails Sphere Fluidics for Enabling Efficient, Faster, and More Cost-effective Single-cell Analysis with Its Microfluidic Platforms
The flexible and easy-to-use microfluidic platforms easily adapt to customers' unique research needs, boost throughput and efficiency, and enhance customers' single-cell research capabilities. SAN ANTONIO, April 11, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European microfluidic platforms for biological screening and discovery market and, based on its findings, recognizes Sphere Fluidics with the 2022 Europe Technology Innovation...
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study. APNmAb005 is a unique antibody that recognizes...
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the annual meeting of American Association of Cancer Research held on Apr 8-13 in New Orleans....
Successful Passing Of The EU Qualified Person Audit Of The Group’s Manufacturing Facility For ReCOV In Taizhou
TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Person Declaration issued by a Qualified Person ("QP")...
CUHK researchers discover distinct gut microbial signatures for prediction, diagnosis and treatment of long COVID
HONG KONG, April 11, 2022 /PRNewswire/ -- Clinical researchers from The Chinese University of Hong Kong's (CUHK) Faculty of Medicine (CU Medicine) have identified for the first time distinct gut microbiome profiles associated with post-acute COVID-19 syndrome, more commonly known as "long COVID". These distinct gut microbial signatures can be used to...
Honeywell Teams with AstraZeneca to Develop Next-Generation Respiratory Inhalers That Use Near-Zero Global Warming Potential Propellant
Next-generation inhaler will use Honeywell's Solstice® Air to reduce greenhouse gas emissions of propellant by up to 99.9 percent vs current inhaler propellant Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products CHARLOTTE, N.C., April 11, 2022 /PRNewswire/ -- Honeywell...
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
The company will present the preclinical data of five novel drug candidates at AACR 2022 (on April 8-13). Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, April 11, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and...
